Aldeyra Therapeutics, Inc.
|Number of Estimates|
Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
Market Cap: 58.4 Million
Primary Exchange: NASDAQ
Shares Outstanding: 29.7 Million
Float: 25.7 Million
Sector: Health Technology
Longest drawdown: 920 trading days
From: 2015-01-30 To: 2018-09-25
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|